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Abstract: Despite the eradication of smallpox several decades ago, variola and 
monkeypox viruses still have the potential to become significant threats to public health. 
The current licensed live vaccinia virus-based smallpox vaccine is extremely effective as a 
prophylactic vaccine to prevent orthopoxvirus infections, but because of safety issues, it is 
no longer given as a routine vaccine to the general population. In the event of serious 
human orthopoxvirus infections, it is important to have treatments available for individual 
patients as well as their close contacts. The smallpox vaccine and vaccinia immune 
globulin (VIG) were used in the past as therapeutics for patients exposed to smallpox. VIG 
was also used in patients who were at high risk of developing complications from smallpox 
vaccination. Thus post-exposure vaccination and VIG treatments may again become 
important therapeutic modalities. This paper summarizes some of the historic use of the 
smallpox vaccine and immunoglobulins in the post-exposure setting in humans and 
reviews in detail the newer animal studies that address the use of therapeutic vaccines and 
immunoglobulins in orthopoxvirus infections as well as the development of new 
therapeutic monoclonal antibodies. 
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1. Introduction 
Orthopoxviridae is a genus of poxviruses that includes viruses such as variola virus (VARV), the 
causative agent of smallpox, vaccinia virus (VACV), the vaccine used to help eradicate smallpox, and 
cowpox virus and monkeypox virus (MPXV), viruses that cause zoonotic infections of humans. These 
are large DNA viruses that encode hundreds of proteins that induce strong, cross-reactive immune 
responses. Thus, infection by one of these viruses results in protection from disease caused by another. 
Despite the successful worldwide eradication of smallpox by the World Health Organization [1], 
VARV and MPXV have the potential to become serious public health threats [2,3]. Live VACV-based 
vaccines were extremely effective in generating remarkably long-lived immune responses [4–6] and 
protection from VARV and MPXV [1]. However, due to serious but rare vaccine complications [7], 
routine smallpox vaccination ceased decades ago. Thus, in the potential setting of new human 
infections with poxviruses, post-exposure smallpox vaccination and/or immunoglobulins may become 
first line therapies. Post-exposure vaccines and immunoglobulins have been successfully used against 
smallpox and other viral infections like those caused by hepatitis A and B viruses, rabies virus, and 
varicella zoster virus [8]. In this article we will discuss some of the old human studies and more 
extensively review the newer animal studies of the therapeutic use of live VACV vaccines in the 
post-poxvirus exposure setting and the use of immunoglobulins for therapy against poxvirus infections. 
2. Post-exposure Vaccination 
2.1. Studies of Post-exposure Vaccination of Humans with Conventional Replication Competent 
Smallpox Vaccines like Dryvax
 or Lister 
While prophylactic vaccination with live VACV vaccines helped eradicate smallpox from plaguing 
humankind, if given after exposure, the vaccine could modify the progress of smallpox disease or even 
prevent it if given within the first few days after exposure. Based on the available information at the 
time, Dixon concluded in his book “Smallpox” [9] published in 1962, that “… I think it is probably 
fair to say that at least 50 per cent of cases where successful vaccination has occurred in the first week 
will get some [vaccine] modification and reduction of severity, whereas when done at a later period the 
number showing such modification is not likely to be over 20 per cent.” 
An old study by Dr. William Hanna, which was recently republished [10], was an early example of 
a report that showed the effect of post-exposure vaccination. Hanna collected smallpox cases 
presenting to a hospital in Liverpool, UK during the early 1900s and found that if a primary or boost 
vaccination was given during the incubation period (i.e. before onset of symptoms), smallpox disease 
could be altered. Because the cases he collected had smallpox, the data did not include cases that might 
have been fully protected by post-exposure vaccination. He reported on 19 cases exposed to smallpox Viruses 2010, 2                  
 
 
2383
that had previously never been vaccinated and were vaccinated during the incubation period. He found 
that two (10.5%) developed no symptoms, eight (42%) showed mild symptoms, seven (37%) showed 
moderate symptoms, and the vaccine did not alter the disease in two (10%) who developed severe 
symptoms. In contrast to vaccination before the onset of symptoms, he reported on 11 cases 
(previously never vaccinated) that were given vaccine after the onset of symptoms. These symptomatic 
patients did not develop the characteristic vesiculopustular lesions following vaccination and three 
(27%) died, five (46%) developed severe disease, and three (27%) showed moderate disease. The 
reasons for not developing characteristic vaccine-related skin lesions could have been due to a failure 
of the vaccination procedure, or in these individuals, who had never been vaccinated, it is possible that 
the immune response to the VARV infection might have suppressed VACV replication (similar to 
individuals who have anti-vaccinia immunity from very recent or multiple vaccinations).   
Post-exposure vaccination was more successful in those previously vaccinated. In the groups that had 
prior vaccination, he reported on 25 cases revaccinated during the incubation period and found that 21 
(84%) showed mild symptoms, three (12%) showed moderate symptoms, and the vaccine did not alter 
disease in one (4%) who developed severe symptoms. In the 19 cases revaccinated after development 
of symptoms, the formation of vesiculopustular lesions after vaccination were poor (perhaps again due 
to development of early immune responses to VARV), and in this group nine (47%) showed mild 
symptoms and 10 (53%) showed moderate symptoms, likely indicating some level of protection from 
their past primary vaccination [10]. 
A similar modification in disease by post-exposure vaccination was suggested by Rao [11]. He 
found that among those given primary vaccination at the time of exposure, 44 of 502 exposed (8.8%) 
developed modified-type smallpox, while only 15 of 1,453 exposed (1.0%) among unvaccinated 
patients developed modified-type smallpox. However, both groups developed ordinary type smallpox 
at similar rates: 85% (426 of 502) in the vaccinated group and 89% (1296 of 1453) in the unvaccinated 
group. Using slightly different outcome measures, Heiner et al. showed a greater effect of   
post-exposure vaccination [12]. In a group of 53 people who were vaccinated within seven days after 
smallpox exposure, only one (1.9%) developed smallpox. While in a group of 412 people exposed to 
smallpox who did not get vaccinated, 90 (21.8%) developed smallpox. However, in this study, it was 
not clear how many of these smallpox exposed people had been previously vaccinated against 
smallpox. Within a larger epidemiologic study of smallpox outbreaks in Pakistan, Mack et al. showed 
some effect of post-exposure vaccination in previously smallpox vaccine naïve patients [13]. They  
identified 43 people who were never vaccinated and exposed to an active case of smallpox. Of those 
who did not get vaccinated within 10 days of the exposure, 26 of 27 (96%) developed smallpox. In 
those who received vaccination within 10 days of the exposure, 12 of 16 (75%) developed smallpox. 
Based on these types of observational studies, which are the only available data on post-exposure 
vaccination, it is generally accepted, that if given early enough after exposure, post-exposure 
vaccination with live VACV vaccines can modify and potentially prevent smallpox disease. That is, 
primary vaccination done early after exposure could at least protect individuals from serious illness 
and revaccination during the first week of exposure of previously vaccinated individuals could prevent 
smallpox. Such conclusions have been reached in a recent analysis of old data sets [14]. Viruses 2010, 2                  
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2.2. Animal Studies of Post-exposure Vaccination with Replication Competent VACV Vaccines 
Since the eradication of smallpox, all data on post-exposure vaccinations for the treatment of 
poxvirus infections have been generated using animal models. In these studies, post-exposure 
vaccination supports the notion that vaccination may provide an effective means to decrease the 
morbidity and mortality from poxvirus exposures in the emergency setting. However, an important 
caveat to all of these studies is that challenge doses and challenge routes do not recapitulate the natural 
acquisition of VARV and MPXV infections. That is, the challenge doses are likely much higher than 
what may normally initiate a natural infection and the routes of infection do not authentically mimic 
natural infection. 
Initial studies with replication-competent VACV vaccine strains did not show protection. For 
example, Staib et al. found no survival when VACV Elstree was given just prior to or after intranasal 
challenge with VACV [15]. In this study, mice were vaccinated with 1  10
6 pfu (plaque forming 
units) VACV-Elstree by scarification 2 days prior to challenge or on day 0, 1, or 2 after intranasal 
challenge with 1   10
6 pfu VACV (strain WR). While vaccination with Elstree at times around 
challenge failed to confer protection against this high dose intranasal challenge, mice vaccinated 14 
days prior to challenge were fully protected. Similar failure of post-challenge vaccination was seen 
with an intratracheal challenge of nonhuman primates with MPXV [16]. Only one of six macaques 
survived a lethal intratracheal challenge with 1  ×  10
7 pfu MPXV if vaccinated with VACV 
Lister/Elstree  strain  (2.5 × 10
5 TCID50) by scarification 24 hours after challenge. The other five 
macaques met end point criteria at ~10 days after challenge. 
However, successful vaccination near challenge could be seen in other types of animal models. 
Paran et al. studied post-exposure vaccination with VACV-Lister against lethal ectromelia (mousepox) 
virus (ECTV) infection [17]. Balb/c mice, which are highly susceptible to ECTV infection, were 
vaccinated with 10
6 pfu VACV-Lister by intradermal or intramuscular routes on the day they were 
intranasally challenged with ECTV (3  LD50). They found that vaccination, by either route, on the 
day of challenge conferred 100% protection and that vaccination, by either route, when given one day 
after challenge resulted in 80% survival. However, when vaccination was given two days after 
challenge, the route of vaccination appeared to slightly impact on survival. They found only a 16% 
survival rate after intradermal vaccination and 40% survival rate after intramuscular post-challenge 
vaccination. They noted that the mean time to death of ECTV infection in Balb/c mice is ~10 days, 
while for intranasal VACV-WR challenge, death occurs in ~6 days. Thus, as opposed to mice 
intranasally challenged with WR [15] or monkeys intratracheally challenged with MPXV [16], the 
protection seen with the VACV-Lister vaccine in ECTV challenged mice could be due to the 
differences the mean time to disease. When compared to VACV challenge, ECTV infection appeared 
to have a longer lag period before the onset of morbidity and mortality. ECTV has a ~7 day incubation 
period, while VACV has only a 2–3 day lag period before the onset of symptoms. The longer time for 
ECTV to cause disease may allow the replication competent vaccine to induce an initial adaptive 
immune response that results in protection. For VACV or MPXV pneumonia models, disease is faster 
and apparently outpaces the time needed for an initial immune response. Indeed, robust protection of 
mice against intranasal VACV challenge could be generated if vaccine was given 14 days prior to 
challenge [15]. Since natural infection with VARV has an incubation period of ~12 days, the ECTV Viruses 2010, 2                  
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challenge-vaccination models support the earlier observations that humans vaccinated at early times 
after VARV exposure could result in less severe disease and even full protection from disease. 
2.3. Animal Studies of Post-exposure Vaccination with Replication Incompetent VACV Vaccines like 
Modified Vaccinia Ankara (MVA) 
Prior to the complete eradication of smallpox, it became clear that there was a need for safer live 
VACV vaccines. This led to the development of more attenuated vaccines like the modified vaccinia 
Ankara (MVA) (reviewed in [18]). MVA was isolated after extended serial passages in chick embryo 
fibroblast cells and the resulting virus, which lost >10% of its genome, no longer produces progeny 
virus in most mammalian cells. In the 1970s, MVA was tested in Germany in over 100,000 people as a 
pre-vaccine to decrease complications from primary vaccination with conventional smallpox vaccine. 
Given current concerns about bioterrorism with VARV and ongoing outbreaks of MPXV, MVA has 
become a lead candidate as a next generation prophylactic smallpox vaccine [18]. The efficacy of 
MVA in post-exposure settings has recently been studied in animal models. Interestingly, these animal 
studies indicate that MVA might provide more rapid protection against lethal poxvirus infections than 
the fully replication competent smallpox vaccines like Dryvax and Lister when standard doses of the 
vaccines are given at times right before or after challenge. This may be due to the fact that MVA no 
longer encodes many proteins involved in evading the host response to infection and thus MVA 
vaccination just prior to or after challenge might result in enhanced innate and/or more rapid adaptive 
immune responses. Also, as discussed below, the improved protection conferred by MVA may also be 
due to the significantly higher standard dose of MVA. Investigations into a better understanding of the 
mechanism by which MVA protects in the therapeutic setting are ongoing. 
This rapid protection by MVA was first shown in mice [15]. As opposed to no survival of mice 
vaccinated with the replication competent VACV-Elstree just prior to or after intranasal challenge  
with 5 × 10
4 pfu of VACV-strain WR, mice intramuscularly vaccinated with 10
8 pfu of MVA were 
protected if the MVA vaccine was given two days prior to intranasal challenge with VACV-WR. 
Significant protection was also seen if the MVA vaccine was given within three hours of challenge. 
However, similar to Elstree vaccination, MVA vaccination failed to protect if given one to four days 
after challenge [15]. 
When compared to Dryvax, more rapid protection by MVA was also seen in a MPXV-challenge of 
nonhuman primates when vaccines were given four days prior to challenge [19]. In this study, 
macaques were intramuscularly vaccinated with 1  ×  10
8 pfu of MVA or intradermally vaccinated   
with  2.5 × 10
5 pfu of Dryvax at 4, 6, or 10 days prior to intravenous challenge with 5 × 10
6 pfu 
MPXV. When macaques were vaccinated 10 days prior to challenge, both the Dryvax and MVA 
vaccinated groups survived, but there was evidence that the Dryvax group did slightly better. Animals 
in this group had no viremia or lesions. Two of four macaques in the MVA vaccinated group 
developed viremia, three developed low numbers of pock lesions, and one had no lesions. When 
macaques were vaccinated six days prior to challenge, the Dryvax and MVA groups had comparable 
protection. Two of four macaques in each group had detectable viremia and all macaques developed 
skin lesions. One macaque in MVA group was sacrificed on day 9 post-challenge because of high 
number of lesions (although its viremia was lower (~1 × 10
5 pfu/mL) than unvaccinated macaques Viruses 2010, 2                  
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(~1 × 10
7 pfu/mL)). When macaques were vaccinated four days prior to challenge, the MVA 
vaccinated group were able to control the infection and survive, while the monkeys in the Dryvax 
group developed viremia and lesion counts similar to the unvaccinated control group and three of four 
in the Dryvax group met end point criteria and were sacrificed by day 10–14. To begin to understand 
the difference in protection conferred by the two vaccines, immune responses were evaluated. A single 
injection of MVA (10
8 pfu) induced a more rapid anti-VACV antibody response than Dryvax   
(10
5 pfu). MVA also induced a more rapid CD8 T cell IFN- response than Dryvax. Based on these 
findings, the authors concluded that the more rapid immune response by MVA compared to Dryvax 
could be due to the fact that MVA is given at a dose that is ~1000-times greater than the Dryvax dose. 
This resulted in a more rapid immune response that improved protection when MVA was given four 
days prior to challenge. It should also be pointed out that when the vaccines were compared in a more 
prophylactic setting (i.e. a single vaccination given 10 or 30 days prior to challenge), and with a  
10-fold higher MPXV intravenous challenge dose (5 × 10
7 pfu), the authors found that while both 
groups survived, the Dryvax vaccinated group was better compared to the MVA-vaccinated group 
based on post-challenge viral loads and skin lesion counts. 
Similar to the above studies, Paran et al. found better protection of mice with MVA vaccination 
when compared to vaccination with a replication competent VACV vaccine [17]. Balb/c mice 
intranasally challenged with ECTV (3 × LD50) were fully protected when intramuscularly vaccinated 
with MVA (10
8 pfu) 1 or 2 days after challenge. When vaccinations were done at 3 or 4 days after 
ECTV challenge, survival rates were 60% and 20%, respectively. When mice were vaccinated 
intradermally with VACV-Lister (10
6 pfu) 1, 2, 3 or 4 days after challenge, survival rates were   
only 83%, 16%, 0% and 0%, respectively. They also found that similar to intradermal vaccination, 
intramuscular vaccination with VACV-Lister (10
6 pfu) at 1, 2, 3 or 4 days after intranasal ECTV 
challenge gave similar survival rates of 80%, 40%, 20% and 20%, respectively. Because the MVA 
vaccine dose was 100-times higher than the VACV-Lister vaccine dose, they compared the vaccines 
given at the same dose (10
6 or 10
8 pfu) by the same intramuscular route of administration in   
Balb/c mice. With the higher vaccine dose (10
8 pfu) given 1, 2, or 3 days after challenge with   
ECTV (5 × LD50), similar levels of protection were seen. Thus, post-challenge vaccinations with the 
higher vaccine doses (10
8 pfu) showed that VACV-Lister could perform as well as MVA. But with the 
lower dose vaccine (10
6 pfu) given 1, 2, or 3 days after challenge, the MVA vaccination   
conferred 100%, 80% and 60% survival rates, respectively, while the VACV-Lister vaccination 
conferred survival rates of 100%, 40% and 40%, respectively. Thus two days after challenge, MVA 
vaccination with 10
6 pfu had a statistically significant higher survival rate than VACV-Lister 
vaccination. Thus, these authors showed that both VACV-Lister and MVA vaccination could confer 
post-exposure protection against lethal dose of orthopoxvirus infection, but the level of protection was 
associated with the vaccine dose. To begin to understand a reason for the differences in protection, 
they measured antibody responses at various times after MVA and VACV-Lister vaccinations (in 
unchallenged mice). As one would expect, they found that intramuscular vaccination with 1 × 10
8 pfu 
of either VACV-Lister or MVA induced higher IgM and IgG antibodies than vaccinations with the 
lower 1 × 10
6 pfu dose. Thus the difference in protection seen when Lister was given at 10
6 pfu and 
MVA was given at 10
8 could be due to the more rapid antibody response when high dose vaccines are 
given. To further investigate a mechanism behind short term protection by the vaccines, they examined Viruses 2010, 2                  
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intranasal MVA vaccination of type 1 interferon receptor deficient (IFNAR-/-) and recombination 
activating gene-1 deficient (RAG-1 -/-) mice. The authors focused on this route of vaccination because 
it appeared highly efficient and a non-invasive route of vaccine delivery. In these experiments, they 
intranasally vaccinated mice with MVA (10
8 pfu) two days before intranasal challenge with   
ECTV (3 × LD50). They observed that the IFNAR-/- mice were protected with just a small amount of 
weight loss. However, the RAG-1-/- mice, which lack mature B and T cells, did not survive challenge. 
Based on these results the authors concluded that type 1 interferon is not essential for MVA-induced 
protection, but adaptive immune responses are needed for the short-term protection generated by MVA. 
Another study that provided insight into how therapeutic MVA vaccination is protecting mice used 
normal and specific knockout mice [20]. They found that TLR-9 deficient (TLR-9-/-) mice were much 
more susceptible to intranasal ECTV challenge than the control C57BL/6 mice. However, these same 
TLR-9-/- mice were protected if at the time of high dose ECTV (10
4 TCID50; ~500 LD50) challenge 
they were simultaneously intranasally vaccinated with 1 × 10
8 TCID50 MVA. They also investigated 
the efficacy of MVA vaccination in TLR-9-/- mice at times after challenge with a lower challenge 
dose of ECTV (10
2 TCID50; ~5LD50) and found full protection of mice intranasally vaccinated with 
MVA at 24 or 48 hours after intranasal challenge with ECTV. However, protection was reduced   
to ~30% survival if mice were vaccinated 72 hours after infection. Similar to the increased 
susceptibility of TLR-9-/- mice to ECTV challenge, type 1 interferon receptor deficient (IFNR-/-) mice 
also had increased susceptibility to intranasal ECTV challenge. Unvaccinated IFNR-/- mice all 
succumb to challenge at 10 days. However immediate intranasal MVA (1 × 10
8 TCID50) vaccination at 
the time of challenge protected mice challenged with 10
2 and 10
3 TCID50 ECTV, but only   
provided 50% and 0% survival rates for 10
4 and 10
5 TCID50 ECTV challenges, respectively. Thus 
these authors also found that MVA-mediated protection is partially independent of type 1 IFN 
responses. To examine the contribution of adaptive immune responses, the authors infected and 
vaccinated RAG -/- mice and found that immediate intranasal MVA vaccination after ECTV challenge 
could not protect, but extended the survival for several days. This data again indicates the need for the 
adaptive immune response to protect mice with therapeutic MVA vaccine. 
This same group extended their studies to show that NK cells, neutralizing antibodies, and T cells 
were needed to protect mice against lethal ECTV infection after post-challenge MVA vaccination [21]. 
In these experiments, C57BL/6 mice were intranasally infected with a lethal dose of ECTV   
(3 × 10
4 pfu) and then vaccinated with MVA (5 × 10
7 pfu) either by intranasal or intravenous routes. 
Intravenous vaccination with MVA on day 2, 3, or 5 post-challenge conferred a survival rate   
of 100%, 100%, and 20%, respectively. Intranasal MVA vaccination at the same time points resulted 
in survival rates of only 30%, 0%, and 0%. To further understand the mechanism of protection 
conferred by post-exposure MVA vaccination, they intranasally challenged and then three days later 
intravenously vaccinated various transgenic mouse strains. They saw that 9 of 11 post-challenge 
vaccinated mice lacking NK and NKT cells (IL-15Ra deficient mice) died (most within 10 days). 
Similarly, in B-cell receptor transgenic mice (T11MT mice), which are unable to produce specific 
anti-poxvirus antibodies, 5 of 6 mice did not survive. These results show the importance of NK cells 
and B-cells in post-exposure MVA vaccination. Interestingly, in mice that are unable to class switch 
from IgM to IgG (AID mice), MVA vaccination protected, with development of anti-pox neutralizing 
IgM antibodies. Similar MVA protection was found with challenged mice that lack the FcR chain Viruses 2010, 2                  
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(which have defects in all Fc-receptors and FcR signaling). When challenge-vaccination studies were 
done in MHC class I (2M-/-) or class II (H2-Ab1-/-) deficient mice, they observed that 15 of 19  
post-challenge MVA vaccinated MHC class II deficient mice died within 10 days, while the MHC 
class I deficient mice survived for three weeks and then only 3 of 12 mice survived beyond 30 days. 
This data indicates that CD4 and CD8 T cells are likely required for protection at different time points 
after post-exposure MVA vaccination. Based on these results, the authors concluded that NK cells, 
production of specific neutralizing antibodies, CD4, and CD8 T cells are essential for protection after 
post-exposure MVA vaccination. Furthermore, these conclusions indicate that the host responses 
required for survival after post-exposure vaccination differs from those involved in prophylactic 
vaccination. In prophylactic vaccination, antibodies and B cell memory alone can provide protection 
against high dose ECTV challenge [22–24]. But protection with post-exposure vaccination requires the 
presence of multiple arms of the immune system [21]. 
2.4. Conclusions 
In conclusion, the animal studies reveal that immediate pre-exposure and post-exposure vaccination 
can protect from lethal challenge, but critical factors such as the lag period before disease of the 
infecting virus and the dose and route of the VACV vaccines impacts on the level of protection. It is 
also important to mention again that these animal models do not mimic natural VARV infection of 
humans. After exposure in humans, the virus replicated initially in lymphoid tissues, then disseminated 
through the bloodstream, perhaps making it more vulnerable to a humoral immune response. By 
contrast, in the animal models that use intranasal virus challenge, the presence of a localized 
respiratory tract infection could bring about the need for a cellular immune response to contribute to 
protection. The animal work with MVA is also quite encouraging since this highly attenuated live 
virus vaccine may actually be a better post-exposure vaccine than the conventional fully replication 
competent VACV vaccines. It is intriguing to consider that the improved protection conferred by 
MVA may depend on its loss of genes encoding immunomodulatory proteins, permitting enhanced 
innate immune responses and/or the more rapid development of an adaptive immune response. Also 
contributing to the enhanced protection is the higher immunogenic load with standard MVA 
vaccination, which is given at 100- to 1000-fold higher doses than the conventional, replication 
competent vaccines. Based on the old observational human studies done prior to the eradication of 
smallpox, it is likely that the fully replication competent vaccines could confer a level of protection in 
previously unvaccinated humans if given within four days after exposure. That window may be even 
wider with MVA. In either case, it appears that post-exposure vaccination could prevent or at least 
limit the severity of illness and thus will be indicated in people with smallpox exposure or even 
uncertain exposure to smallpox. 
3. Vaccinia Immune Globulin (VIG) 
Vaccinia immune globulin (VIG) is currently the only product that is approved by the FDA for 
treatment of complications from VACV vaccination and might have therapeutic efficacy in systemic 
orthopoxvirus infections caused by variola or monkeypox viruses. VIG is an isotonic sterile solution 
obtained by plasmaphoresis of people who were previously vaccinated with VACV and have high Viruses 2010, 2                  
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anti-VACV antibody titers [25]. In the past, VIG, administrated by the intramuscular route, was used 
to treat complications of smallpox vaccination. Due to limited stocks of the old preparations of VIG,  
in 2005, the FDA approved Dynport Vaccine Company LLC (USA) to manufacture new stocks of 
VIG. The new stocks of VIG can be administered intravenously (VIG-IV). In addition to being a less 
painful way to administer large volumes of VIG, intravenous administration seems to have more 
favorable pharmacokinetics than does VIG administrated intramuscularly [26]. When given 
intravenously, the geometric mean titer of VIG (given at a dose of 100 mg/kg) is 2.5-times higher than 
after intramuscular injection. Also, intravenous administration of higher doses (e.g., 200 mg/kg   
or 500 mg/kg), which would be difficult to give intramuscularly, is well tolerated. The older 
intramuscular VIG preparation contained the antimicrobial preservative thimerosol and was therefore 
contraindicated in pregnancy because of potentially teratogenic effects [27]. Although this specific risk 
does not exist with the newer intravenous preparations of VIG, VIG-IV is not recommended for use in 
pregnancy since it could potentially induce other adverse effects. However, it has been pointed out that 
antibody preparations used in pregnant women for the prevention of Rh incompatibility and treatment 
of idiopathic thrombocytopenic purpura are produced by the same processes as VIG-IV and have been 
safely administered to pregnant women [27]. 
The potency of VIG is defined by its ability to neutralize mature virus (MV, also called intracellular 
mature virus or IMV). However, during infection multiple forms of infectious virions are formed. The 
MV is a more stable form of the virus and is believed to be the form that is transmitted from 
host-to-host. The other important form of infectious virus is called the extracellular virus (EV, also 
called extracellular enveloped virus (EEV)), which is critical for spread of the virus from cell-to-cell 
and to distant sites within a host. Given the importance of EV in pathogenesis, activity of VIG against 
EV has also been examined. The major target of EV neutralizing antibody in VIG is against the 
EV-specific B5 protein [28,29]. VIG also contains antibodies that react with viral encoded immune 
evasion molecules (e.g., [30]), which could also play a role in its anti-poxvirus activity. Researchers 
have begun to try to identify all of the VACV targets in VIG [31,32]. Due to the highly homologous 
proteins encoded by orthopoxviruses, there is a high degree of shared serologic cross reactivity. Thus 
VIG could react with proteins from other orthopoxviruses and have similar therapeutic effects against 
other poxvirus infections. 
VIG was first introduced into clinical use to treat the complications of smallpox vaccinations by  
Dr. Henry Kempe, a pediatrician practicing at the University of Colorado [33]. Kempe championed the 
use of VIG based on his astute clinical observations. He reasoned that antibodies could protect from 
VACV infections because he observed that the natural passive transfer of maternal anti-vaccinia 
antibodies to babies resulted in unsuccessful smallpox vaccination of some recently born babies [34]. 
He further believed that the development of the post-vaccination complication known as eczema 
vaccinatum was due to a delay in antibody production and that progressive vaccinia resulted from a 
complete failure to produce anti-vaccinia antibodies [33]. Thus, he was convinced that giving antibody 
as hyperimmune vaccinal gamma globulin (we will call this product VIG) could help patients who 
developed serious complications from smallpox vaccination. He modified this hypothesis in the late 
1960s when he recognized that children with X-linked Bruton agammaglobulinemia could be safely 
vaccinated without vaccine related complications, but infants who had defects in delayed-type 
hypersensitivity reactions (now known as severe combined immunodeficiency) developed progressive Viruses 2010, 2                  
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vaccinia [35]. Thus, he believed that both cellular and humoral immune responses were important to 
control the infection [36,37]. Initially, Kempe studied the therapeutic use of VIG in a limited clinical 
trial in India to examine its usefulness after smallpox exposure [33]. In the 1960s, Kempe started to 
produce purified immunoglobulin and administered it to patients in the U.S. with serious vaccinia 
vaccination complications. Of note, no controlled clinical trials with VIG were ever done, but VIG 
became the accepted treatment based on the impression that treatment resulted in improvement. 
3.1. Prevention and Treatment of Eczema Vaccinatum with VIG in Humans 
Eczema vaccinatum is a rare, but potentially life-threatening illness that can occur in some people 
with atopic dermatitis or eczema that are exposed to VACV either by vaccination or by coming into 
contact with someone who has recently been vaccinated. Clearly not all people with these skin 
disorders develop eczema vaccinatum. The immune defects in the subset of patients at risk of 
developing eczema vaccinatum has not yet been fully defined, but animal models have implicated both 
innate and cellular responses (e.g., [38–40]). In 1956, Kempe et al. reviewed the prophylactic and 
therapeutic value of VIG to prevent and treat complications of smallpox vaccination [41]. They found 
that VIG protected children with skin conditions from developing complications of smallpox 
vaccination if VIG was given at the same time as smallpox vaccination. In this work, eight   
vaccinia-naïve children with eczema (three were <1-year old) required vaccination before going into 
an area where smallpox was endemic. The children received smallpox vaccination on normal skin and 
at the same time were given a single intramuscular injection of VIG. All the children developed the 
characteristic vesiculopustular lesion following primary vaccination, but none developed 
complications from vaccination. They also reported on the use of VIG in at risk children after direct 
vaccinia vaccination or after contact with someone recently vaccinated. The authors reported on six 
infants <18 months with eczema who were given VIG after a known accidental exposure to the 
vaccine. None of these children developed eczema vaccinatum [41]. The paper also reported on the 
treatment of eczema vaccinatum with VIG. Fourteen infants presenting with fairly severe eczema 
vaccinatum were treated with VIG once (or given a second dose later on). The first dose of VIG was 
given 2 to 5 days after presenting with eczema vaccinatum. In most cases, the children recovered, but 
there were two deaths that occurred on day 1 and day 3 after VIG administration. Both of the infants 
who died were already in a critical condition when VIG was started and the VIG was started five days 
after the onset of symptoms. A better outcome of eczema vaccinatum when treated early after 
presentation was illustrated in a recent report of this VACV vaccine related complication [42]. In this 
case, a two-year old child with a history of eczema and failure to thrive had a delay in treatment with 
VIG because the history of exposure to a parent who had been recently vaccinated with VACV was 
not immediately obtained. VIG treatment was begun ~12 days after the potential onset of symptoms. 
Despite VIG treatment, the rash progressed and the child became critically ill requiring life support 
measures. At that point, in addition to VIG, the child was treated with cidofovir and an investigational 
new anti-poxvirus drug. Fortunately, the child ultimately recovered after a two-month hospitalization. Viruses 2010, 2                  
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3.2. Use of VIG in Humans with Progressive Vaccinia and in Immunocompromised Animal Models 
Kempe also used VIG to treat progressive vaccinia (at the time also known as vaccinia 
gangrenosum) and showed that some VIG treated children could survive this previously universally 
fatal disease [33,41,43]. In an excellent review on progressive vaccinia, Bray and Wright collected 41 
reports of VIG treatment of progressive vaccina in children and adults from 1955 to 1997 [44].   
Among 17 children with progressive vaccinia treated with VIG ( the antiviral drug methisazone), 
three (18%) survived. These three survivors had only partial immunodeficiencies like 
hypogammaglobulinemia. In the 14 children that died despite VIG treatment, seven had combined 
immune deficiencies, four had a cell-mediated deficiency and three had hypogammaglobulinemia, 
Among 24 adults with progressive vaccinia treated with VIG, 13 (54%) survived. Ten of these 13 
survivors were individuals who developed immunodeficiency because of leukemia or lymphosarcoma 
treated with chemotherapy. Thus, VIG treatment of progressive vaccinia is more successful in adults 
than children, because adults with acquired immunodeficiencies were likely less immunosuppressed 
than the children. With that said, there is a case report of an adult with combined variable 
immunodeficiency that survived progressive vaccinia after treatment with VIG and methisazone [45]. 
Similar to the poor outcomes of immunocompromised children with progressive vaccinia treated 
with VIG, vaccinia infected mice with severe combined immune deficiency (SCID) treated with VIG 
also succumb to infection. In one study, the antiviral efficacy of VIG was studied in SCID mice 
infected with a recombinant VACV expressing the rabies virus glycoprotein [46]. SCID mice 
underwent intradermal scarification with 10
6 pfu of the recombinant VACV on the dorsal surface of 
the tail with a bifurcated needle. Mice were then treated with an intramuscular dose of VIG (20 L, 
which represented 1.2 mL/kg or ~200 mg/kg of VIG) three times per week until day 34 post-infection. 
While during the first 14 days after infection, treated animals had significantly smaller tail lesions than 
untreated controls, both treated and untreated mice needed to be euthanized between day 25 and 34 
because of progressive lesions or 20% weight loss. Interestingly, in this study the authors also 
combined VIG treatment with HPMPC (an acyclic nucleoside analog with anti-vaccinia activity) and 
showed that this group of treated mice did the best with smaller lesions, and no new skin lesions when 
therapy was stopped. All mice in this group survived until the experiment was terminated at day 65. 
The use of VIG along with an antiviral to treat poxvirus infections was a concept that Kempe also 
recognized as a potential way to treat progressive vaccinia [47]. 
In another study that looked at the biological activity of VIG-IV in SCID mice, Shearer et al. gave a 
single intravenous dose of VIG to SCID mice that were challenged with VACV [48]. In this study, the 
VACV challenge route was intravenous, but we are including it in this section on vaccine related 
infections because the challenge virus was the vaccine Dryvax (administered at a dose of 3  10
4 pfu). 
Thus, this might represent a stage of viremia after vaccination in an immunocompromised host. They 
treated mice with a single dose of VIG (either 2.0 mg (100 mg/kg) or 8.0 mg (400 mg/kg)) the day 
prior to challenge, right after challenge (day 0), or on days 1, 2, 4, 6 or 8 after challenge. When given 
the day prior to challenge, both doses of VIG-IV prolonged survival. The 8 mg and 2 mg doses  
gave 80% and 40% survival, respectively, at day 49 (when the experiment was terminated). All 
untreated control mice succumbed to infection by about day 40. A somewhat similar result was found 
in mice treated immediately after intravenous challenge, with the 8 mg and 2 mg doses giving 80%  Viruses 2010, 2                  
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and 20% survival, respectively. With each additional day after challenge when VIG was administered, 
the trends showed treatment to be less and less effective with decreasing survival rates and survival 
times in the treatment groups. By day 6 after challenge, the initiation of VIG treatment resulted in 
identical outcomes as the untreated controls. Thus, in hosts with severe combined immunodeficiency, 
VIG treatment can extend survival, but cannot cure the VACV infection. 
3.3. Use of VIG in Humans after Exposure to Variola Virus 
While the early use of VIG was examined to treat complications of VACV vaccination and after 
exposure to VARV, it is important to emphasize the differences in pathogenesis between a VACV skin 
lesion and the disseminated disease caused by VARV. During normal vaccination, the immune system 
must detect, control, and ultimately eliminate spread of virus at a single cutaneous site. T-cells 
responses (either CD8
+ T cells or T helper cell-dependent antibody responses) are critical for   
control [49,50]. In smallpox, an inhaled dose of virus initially replicates in lymphoid tissues, then 
disseminates through the bloodstream. So the presence of protective antibodies through prior 
vaccination is a critical component in the protective immune response [22–24]. Thus the potential use 
of VIG after exposure to VARV has some rationale. 
In 1953, Kempe examined the use of VIG in patients in India who had been exposed to family 
members with smallpox [33]. He studied 131 family contacts of 29 proven smallpox cases that were 
admitted to the Madras Infectious Disease Hospital. The contacts were alternately assigned to a group 
that received smallpox vaccination only or to a group that received vaccination and VIG. Among 75 
contacts that received vaccination alone, there were eight (10.7%) secondary cases of smallpox. Five 
of these eight cases occurred in children under five years old and three of these children, who were all 
infants, died of smallpox. In the group of 56 contacts who received vaccination and VIG, there were 
only two (3.6%) secondary cases of smallpox. One of the smallpox cases was fatal and the other case 
developed mild disease. It is important to point out that both the vaccine only group and the vaccine 
plus VIG group had the same proportion of children under five years old. Kempe concluded that  
post-exposure smallpox vaccination along with VIG conferred better protection than vaccination   
alone [33]. These findings were replicated in a larger study [51]. In this study, among 326 contacts 
receiving VIG followed by vaccination, five (1.5%) cases of non-fatal smallpox developed while 
among 379 contacts that received vaccination alone there were 21 (5.5%) cases of non-fatal smallpox. 
Combined, these two studies showed ~70% reduction in secondary smallpox in groups that received 
VIG and vaccination when compared to vaccination alone. Similar positive results with VIG were seen 
in a review [52] that collected a number of case reports of the use of VIG after prolonged exposure to 
smallpox. In these reports [53–55], all patients were vaccinated after exposure, but given the prolonged 
exposure times to the cases of smallpox, they were all felt to be beyond the window where therapeutic 
vaccination would be successful. Thus, 13 adults and 16 children were treated intramuscularly with 
VIG. All were protected except one adult and one child (both from the same report [54]) who 
developed very mild cases of smallpox. Similarly, in a report of 42 people who had close contact with 
cases of smallpox and some with delayed post-exposure vaccination, Marennikova showed a potential 
benefit of VIG [56]. None of the 13 contacts that were intramuscularly treated with VIG 5 to 22 days 
after exposure developed smallpox. Of note, 10 of these 13 received post-exposure vaccination five or Viruses 2010, 2                  
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more days after exposure. While none of these patients who received VIG developed smallpox, 13 
(45%) of the 29 contacts that did not receive VIG developed smallpox. In this same report, 
Marennikova also reported the use of VIG to treat four patients with smallpox. Two of these patients 
(a 40 year old and an eight year old) were in the prodromal period and were given multiple doses of 
VIG on the third and fourth day of disease. They both had very mild disease with one being classified 
as smallpox without eruption. She also treated two patients with VIG “at the height of the disease” and 
observed that after treatment the patients clinically improved and lesions may have resolved more 
quickly [56]. Based on this human data, after a known smallpox exposure, VIG (along with 
vaccination) would be indicated. This will be particularly important in unvaccinated contacts. The use 
of VIG along with vaccination in people exposed to smallpox could help limit the spread and also 
lessen the mortality from an outbreak. 
3.4. Use of VIG in Animal Models to Treat Orthopoxvirus Infections 
The use of VIG for post-exposure treatment of poxvirus infections has been reexamined using 
various animal models. The therapeutic value of a rabbit vaccinia-immune IgG was investigated in 
mice intranasally challenged with VACV (strain WR) [57]. Law et al. found that giving hyperimmune 
anti-vaccinia rabbit antibody on day 3 post-infection was almost as protective as antibody given one 
day before infection. However, if the antibody was given four days after infection, poorer protection 
(as measured by weight loss) was seen [57]. Lustig et al. reported similar results with VIG in ECTV 
and VACV-WR challenge models [58]. If mice were intraperitoneally treated with a single dose of 
VIG (8 mg, 450–500 mg/kg) one day before or one day after challenge, full protection was obtained 
against intranasal challenge with lethal ECTV infection (5 × LD50). Even when VIG was given two or 
three days post-challenge, it conferred 60–80% protection. Interestingly, while VIG treatment given 
either one day prior or 1 day after intranasal challenge with VACV-WR (10
5 pfu, ~5  LD50) resulted 
in 100% survival, both the pre and post-treatment groups had significant weight loss of >30%. This 
again shows that the differences in the pace of infection by the challenge viruses (and the subsequent 
ability of the host to mount a response to the infection) impacts on morbidity. 
VIG has also been studied as treatment for systemic poxvirus infections in immunocompromised 
mice. The study by Lustig et al. also examined VIG treatment of SCID mice infected with   
VACV [58]. They either gave a single intraperitoneal injection of VIG (8 mg, 450–500 mg/kg) 
24 hours prior to intranasal VACV-WR challenge (1.2 × 10
3 pfu; ~5 × LD50) or alternatively they 
administered 8 mg VIG prior to challenge followed by repeated injections of 2 mg VIG every other 
day for 18 days (thus a total VIG dose of 26 mg was given to the repeated dose group). As opposed to 
the untreated SCID mice, which all died by day 11 after challenge, the mice that received a single dose 
of VIG prior to challenge survived until day 16. The group of SCID mice that received repeated doses 
of VIG survived longer (100% at day 18, but 0% by day 22). Also in the group that received repeated 
VIG treatment, the mice had an early plateau in weight loss during the first week post-challenge, but 
then showed continuous weight loss until death. Again it seems that prolonged VIG treatment can 
extend survival, but adaptive immune responses are eventually needed for recovery. 
These data in immunocompetent and immunocompromised animals suggest that high dose VIG 
treatment at times just prior or after a lethal orthopoxvirus challenge can alter disease. However, since Viruses 2010, 2                  
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these models use challenge doses and challenge routes that do not mimic natural acquisition that have 
a longer asymptomatic incubation period prior to the onset of disease, one potentially can look at this 
type of animal data as showing the likely effectiveness of antibody treatment if given during the 
incubation period. However, the benefit of antibody treatment greatly diminishes with the onset of 
symptoms. 
3.5. Conclusions 
In conclusion, VIG is the only product in the U.S. for treatment of complications of vaccinia 
vaccination. It gained approval at a time when specific antiviral drugs did not exist and antisera were 
the mainstay of infectious disease therapy. Once smallpox was eradicated, there was no motivation to 
develop antiviral therapies, so VIG remained the only licensed product. If smallpox had first appeared 
as a disease in the 1980s or later, it seems certain that the therapeutic approach would have focused on 
antiviral drugs and not on antibodies. Our current use of VIG therefore reflects its history, not its 
efficacy. While Kempe’s early observations that maternally transferred antibody to newborns 
prevented successful vaccination, VIG treatment does not prevent the formation of the 
post-vaccination vesiculopustular lesion. This finding allows successful VACV vaccination in the 
setting of concurrent VIG. But this finding also indicates that in the absence of other immune 
responses, VIG alone cannot fully control the resolution of a primary vaccination lesion. Currently 
there are two intravenous formulations of VIG (Dynport and Cangene) that have been issued a license 
by the FDA. Intravenous VIG formulations have advantages over the old intramuscular VIG 
preparations since it is easier to administer large volumes, distributed more rapidly, and contains no 
mercury derivatives. Experimental results in animal models support a role for VIG in prophylaxis and 
treatment of orthopoxvirus infections in animals with a functioning immune system. A more limited 
role is found in animals with severe combined immune deficiencies. Similarly in humans, VIG has a 
role in prophylaxis and treatment of eczema vaccinatum and in post-smallpox exposure prophylaxis 
(along with vaccination). Its use in immunocompromised hosts with progressive vaccinia has shown 
that it can alter what was a uniformly fatal complication from VACV vaccination. However, the 
efficacy in some patients with progressive vaccinia (and not others) is likely due to some patients 
having a partially functioning immune system. Thus, in order to enhance survival of patients where 
VIG has been ineffective, it will be important to improve immunoglobulin therapies. The current 
development of specific monoclonal antibodies to enhance VIG’s activity and/or specific anti-poxviral 
drugs that can be used with VIG might improve outcomes of patients with severe combined 
immunodeficiencies. 
4. Anti-poxvirus Monoclonal Antibodies as Future Therapeutics 
While VIG is believed to be effective in the treatment of early stages of eczema vaccinatum, its 
limited efficacy in treating progressive vaccinia and smallpox disease has lead researchers to pursue 
ways to augment the activity of anti-poxvirus immunotherapy. While some may think that in modern 
times, where careful screening of adults who require smallpox vaccination diminishes the need for the 
improvement of a VIG product, the continued rare, but serious adverse events after VACV vaccination 
show that screening cannot be 100% effective [42,59]. Furthermore, in the setting of the emergency Viruses 2010, 2                  
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use of smallpox vaccination in the outbreak setting, the reliance on screening may become even more 
difficult. Also, while the development of a more attenuated live VACV vaccine (e.g., MVA), may 
allow safer vaccination of people deemed at higher risk from complications from the conventional 
vaccine, here again in the emergency setting, where the conventional vaccine may be used, vaccine 
related complications could still arise. Thus, improving VIG is important in biodefense preparedness. 
Future approaches may be to include monoclonal antibodies (MAb) to increase VIG’s potency or to 
develop a defined cocktail of MAbs that may some day replace VIG. Development of a defined set of 
MAbs to replace VIG has the additional advantage of moving away from an immunoglobulin product 
that relies on human donors. This is not only important because of the ever present danger of human 
blood products containing an unscreened infectious agent, but the need for a non-human source 
product was highlighted in a recent report of the massive amounts of VIG used to treat a patient 
suffering from progressive vaccinia [59]. The patient was given a total of 16.7 million units of VIG. 
This amount of VIG was 30-times greater than the anticipated use of VIG for vaccine-related 
complications. This brings into question the amount of VIG in the national supply should widespread 
smallpox vaccination become necessary. There is some debate about the amount of VIG that was used 
to treat this specific patient, and whether VIG treatment was being used to control the lesion at the 
vaccination site, which as mentioned earlier may not be attainable with VIG alone. Nevertheless, to 
find alternatives to VIG, researchers have mainly focused on the generation of MAbs to the surface 
proteins on the two major forms of infectious VACV, mature virus (MV) and the extracellular virus 
(EV) [60–62]. Key neutralizing antibody targets on the MV envelope are encoded by the A27L [63], 
A28L [64], D8L [65], H3L [66], and L1R [67,68] genes. The A33R and B5R genes encode key 
antibody targets on the EV envelope [69]. 
One of the first identified targets of neutralizing monoclonal antibodies was the 14-kDa   
protein [63] encoded by the A27L gene. The VACV A27 protein is found on MV and is highly 
conserved among orthopoxviruses. Ramirez et al. used the anti-A27 mouse MAb C3 and studied its 
ability to protect Balb/c mice following a single administration either before and after VACV 
challenge [70]. Groups of mice were pretreated intraperitoneally with 10 or 100 g of purified MAb 
C3 and then one hour later were intraperitoneally challenged with a lethal dose (1 × 10
8 pfu) of a 
recombinant VACV expressing luciferase (WRluc). Mice pretreated with either dose of MAb C3 
survived challenge, but untreated control mice died within three days after infection. Using whole 
mouse imaging, they also examined luciferase levels in target organs (ovaries and spleens) from mice 
that were first pre-treated with 1, 10, or 100 g of MAb C3 and then intraperitoneally challenged one 
hour later with a lower dose (5 × 10
7 pfu) of WRluc (so that mice would survive to day 5). When 
compared to untreated controls, luciferase levels were markedly reduced in organs of mice pretreated 
with 10 or 100 g MAb C3. Since both the antibody and challenge virus were delivered 
intraperitoneally, the survival and decreased spread to organs could have been due to near complete 
neutralization of the challenge virus. Thus, they also examined post-challenge treatments. They 
intraperitoneally infected groups of mice with a sub-lethal dose of WRluc (2.5  ×  10
7 pfu) and 
measured virus spread in organs by whole mouse imaging. When compared to untreated mice, groups 
treated with 10 g MAb C3 on days 1, 2, or 3 after challenges had decreased amount of virus in 
organs. These results showed that in a non-lethal intraperitoneal challenge model, an anti-A27 
antibody could alter the spread of virus in the organs if given up to three days after infection. In Viruses 2010, 2                  
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addition to this, they also looked at survival of mice treated with MAb C3 (10 g) one day after the 
higher dose (1 × 10
8 pfu) lethal intraperitoneal challenge. While the mice pre-treated with MAb C3 
were fully protected, the mice that were treated one day after challenge developed weight loss and 
limited survival. The poorer outcome of post-challenge treatment with antibodies to a MV target was 
confirmed in other studies that used an intranasal VACV challenge [71,72]. In these studies either 
mouse MAbs or rabbit polyclonal antibodies raised to another MV target (L1) conferred some 
protection if given prior to challenge, but provided poorer protection if given after challenge. As 
discussed next, these results support a model where a cocktail of antibodies to at least one MV target 
and one EV target would provide the best therapeutic effect [71]. 
While it makes sense that anti-MV antibodies help control the initial infecting MV inoculum, 
antibodies to EV are likely important in helping to control spread of an established infection. The 
protective role of individual anti-EV proteins were first shown by Galmiche et al. [69]. They tested 
rabbit antibodies raised to EV proteins A33, A34, A36, and B5 and found that subcutaneous 
administration of polyclonal rabbit antibody raised to A33 or B5 (10 g/per injection, four-times   
at 2-week intervals; first dose given prior to challenge) protected mice against intranasal challenge 
with 10
7 pfu of VACV (strain IHD-J). Interestingly, while the anti-B5 antibodies had EV neutralizing 
activity in a plaque reduction assay, the anti-A33 antibodies were non-neutralizing. However, the 
anti-A33 antibodies (and anti-B5 antibodies) had anti-EV activity as measured by an EV-dependent 
spread assay called a comet inhibition assay. 
Lustig et al. compared the protective effect of individual and combinations of mouse MAbs raised 
to A33, B5, and L1 [71]. They found that mice treated with a combination of anti-MV and anti-EV 
antibodies two days after challenge provided superior protection against lethal intranasal WR infection 
than treatment with antibodies raised to a single target. In these experiments, they treated mice with a 
combination of anti-A33 and anti-L1 MAbs (100 g of each) after an intranasal lethal challenge with 
VACV-WR (1  10
6 pfu) and obtained 80 to 100% survival rates (with a maximum weight loss of  
~10 to 20%). However, treatment with a MAb raised to a single target gave 60–70% survival rates 
(with higher maximum weight loss of ~25%). The study also examined treatment of infected SCID mice 
with the combination of antibodies. They intraperitoneally treated SCID mice with either a mixture of 
anti-A33, -B5, and -L1 polyclonal rabbit antibodies (1.67 mg of each) or with a mixture of anti-A33,  
-B5, and -L1 MAbs (100 g each). Twenty-four hours after antibody treatment, they intranasally 
challenged the SCID mice with either 10
6 pfu (4000  LD50) or 10
4 pfu (40  LD50) of VACV WR. 
While all untreated mice challenged with 10
6 pfu ultimately died, a one-time treatment with antibodies 
prior to challenge resulted in extended survival times when compared to the untreated controls. That is, 
while untreated controls all died within 11 days, mice treated with the rabbit polyclonals or MAbs  
had 50% survival times of 26 days and 46.5 days, respectively. Encouragingly, 40% of mice treated 
with the cocktail of MAbs and challenged with the lower WR dose (10
4 pfu), survived more than three 
months (when the experiment ended), while untreated controls all died within two weeks. 
Progress had been made in developing MAbs that would be suitable for human use. Chen et al. 
developed two chimpanzee/human anti-B5 MAbs that have high binding affinities to B5 [73]. In vitro, 
these antibodies could inhibit comet formation by VACV and VARV. In vivo, the MAbs provided 
significant protection against VACV challenge when given to mice two days after challenge. They 
found that intraperitoneal treatment with 90 g of the chimpanzee/human anti-B5 MAb (8AH8AL)  Viruses 2010, 2                  
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48 hours after intranasal lethal challenge with VACV-WR (5 × 10
5 pfu) protected mice from death 
(but they had weight loss of ~15%). The group of mice that were not treated died within seven days 
after challenge. In these experiments they included a group of mice treated with a single dose of  
VIG (5 mg/mouse, ~250 mg/kg) two days after challenge. VIG treatment afforded less protection than 
the chimpanzee/human anti-B5 MAb with a survival rate of 60%. Since the MAbs are therapeutic 
when administrated two days after exposure, the authors suggested that these MAbs may be a future 
alternative to VIG for treatment of complications from smallpox vaccination. 
This group of investigators also isolated three anti-A33 chimpanzee/human antibodies, which had 
high binding affinities to A33 [74]. Similar to the anti-B5 MAbs, they showed that the anti-A33 MAbs 
reduced the spread of VACV in vitro by a comet inhibition assay. The MAbs also effectively protected 
mice from VACV infection, even when administrated two days after challenge. In these experiments, 
groups of mice were intranasally challenged with a lethal dose of VACV-WR (5  10
5 pfu) and  
then 48 hours later the mice were treated with either 90 g of a single MAb or a combination of an 
anti-A33 and anti-B5 MAb (45 g of each MAb) or VIG (5 mg). All treatments protected mice from 
death. Again they found that post-challenge treatment with the anti-B5 MAb (8AH8AL) provided the 
best protection (with <5% weight loss). The group treated with the anti-A33 MAb (6C) had ~16% 
weight loss (which was similar to the VIG treated group). The combination of anti-B5 and anti-A33 
MAbs provided slightly better protection than anti-A33 alone with ~7% weight loss). While the mouse 
experiments indicate that these anti-A33 MAbs are not as potent as the anti-B5 MAbs, the anti-A33 
MAbs could have better activity in a non-human primate model. 
While studies of anti-poxvirus antibodies have mainly focused on the direct neutralizing activity of 
the antibodies, the in vivo activity of therapeutic antibodies may also be enhanced by effector functions 
of the Fc domain on the antibody (e.g., [75]). For example, Benhnia et al. showed that the 
neutralization of EV by anti-B5 MAbs (with the proper Fc domain) is enhanced in the presence of 
complement [76]. These investigators also showed that because EV proteins are expressed on the 
surface of infected cells, the complement fixing MAbs could also promote complement mediated lysis 
of VACV infected cells. In mouse experiments they found that the level of protection conferred by 
passive transfer of an anti-B5 MAb is diminished if complement is transiently depleted. That is, in 
non-complement depleted mice first passively transferred with a single 100 g dose of an anti-B5 
mouse MAb, B126, survived intranasal challenge of VACV strain WR (5 × 10
4 pfu; 1 to 3  LD50) and 
showed no weight loss. In complement-depleted mice (by treatment of mice with cobra venom factor), 
the passively transferred MAb protected mice from death, but the mice had ~15% weight loss after 
challenge. These data show the potential importance of complement for clearance of EV and VACV 
infected cells. Follow-up studies with human MAbs raised against B5 have confirmed that the Fc 
domain can alter the functional activity of the antibody in both complement dependent EV 
neutralization assays, as well as in direct complement-dependent cytotoxicity of VACV-infected   
cells [76,77]. 
Besides the approach of using therapeutic antibodies that target viral envelope proteins, another 
strategy for therapeutic antibodies would be to target viral proteins that are important for virulence. 
Orthopoxvirus, such as VARV, VACV, and ECTV, encode multiple immune response modifiers that 
are important for virulence [78]. One example of such a protein encoded by poxviruses is the type 1 
interferon binding protein (IFN-bp). Xu et al. showed that it is essential for ECTV virulence and could Viruses 2010, 2                  
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be an effective target for protective immunization [79]. In this work, a recombinant ECTV in which 
the gene encoding the IFN-bp was deleted was >10
7-fold attenuated in Balb/c mice infected by the 
footpad route with 3000 pfu of ECTV. The investigators also showed that the IFN-bp could be used as 
a subunit prophylactic vaccine to protect against subsequent ECTV challenge. This opens the 
possibility that antibodies raised to such immune response modifiers could be used in passive therapy 
of poxvirus infections. 
In conclusion, MAbs generated to proteins on the two major forms of infectious VACV, mature 
virus (MV) and the extracellular virus (EV), have prophylactic and therapeutic effects against 
orthopoxvirus infections. Combinations of MAbs that recognize both MV and EV targets provided the 
best therapeutic effect. Replacing VIG, which requires human donors, with a defined cocktail of MAbs 
or the use of MAbs to enhance the activity of VIG, especially in immunocompromised hosts, is quite 
promising. 
5. Conclusions 
Given concerns about serious human orthopoxvirus infections that can be transmitted from 
person-to-person or are continuously introduced into human populations from a zoonotic source, it is 
important to have strategies for their efficient and immediate treatment. The conventional 
VACV-based live smallpox vaccine was an incredibly successful prophylactic vaccine that helped 
eradicate smallpox. Limited clinical studies also showed that if given early enough after exposure to 
VARV, the vaccine could modify and potentially prevent smallpox disease. More recent animal 
studies support the use of post-exposure vaccination, especially the mouse models that use ECTV 
challenge, which has a lag period before the onset of disease. It is also interesting that animal studies 
have revealed that when compared to conventional VACV vaccines, the MVA vaccine, which does not 
replicate in most mammalian cells, provides more rapid protection against lethal poxvirus. But this 
may be due to the higher doses used with MVA vaccination. Importantly, the animal studies have 
shown that the protection conferred by therapeutic vaccination is not simply through activation of 
innate immune responses, but that adaptive immunity must develop for protection. The use of VIG 
along with VACV vaccination also appears to be a useful strategy for those exposed to an active case 
of smallpox. Clinical work with VIG has shown it to have prophylactic and therapeutic value in 
preventing and treating vaccine-related complications like eczema vaccinatum. However, its efficacy 
to treat progressive vaccinia, especially in the patients with severe combined immunodeficiencies, is 
less encouraging. Animal studies of the therapeutic efficacy of VIG to treat systemic poxvirus 
infections in immunocompetent mice have demonstrated efficacy in post-exposure treatment of 
ECTV-challenged mice. The development of potent anti-poxvirus monoclonal antibodies, many that 
are now in a form suitable for human use, show great promise. They can be used to enhance the 
potency of VIG or to create a defined cocktail of antibodies, which also has the advantage of not 
relying on human donors. 
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